Voloridge Investment Management LLC Has $15.41 Million Stake in Natera, Inc. (NASDAQ:NTRA)

Voloridge Investment Management LLC trimmed its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 40.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 97,320 shares of the medical research company's stock after selling 66,847 shares during the period. Voloridge Investment Management LLC owned approximately 0.07% of Natera worth $15,406,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its position in shares of Natera by 134.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after buying an additional 3,871,862 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Natera by 43.7% in the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock worth $1,060,836,000 after purchasing an additional 2,036,396 shares in the last quarter. Norges Bank bought a new stake in shares of Natera in the 4th quarter worth approximately $224,040,000. Raymond James Financial Inc. bought a new stake in shares of Natera in the 4th quarter worth approximately $146,419,000. Finally, Vanguard Group Inc. increased its position in shares of Natera by 7.7% in the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after acquiring an additional 879,463 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Up 2.5%

NTRA stock traded up $3.84 during trading hours on Tuesday, hitting $157.16. The company's stock had a trading volume of 1,040,284 shares, compared to its average volume of 1,391,432. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $21.46 billion, a PE ratio of -89.30 and a beta of 1.79. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00. The stock has a 50 day moving average price of $149.44 and a two-hundred day moving average price of $158.04.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. During the same period in the previous year, the firm posted ($0.56) earnings per share. The company's revenue for the quarter was up 36.5% compared to the same quarter last year. On average, equities research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Barclays lifted their target price on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Robert W. Baird lifted their target price on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Morgan Stanley lifted their target price on shares of Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $180.00 price objective on shares of Natera in a research report on Wednesday, February 26th. Finally, UBS Group boosted their price objective on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, Natera presently has a consensus rating of "Moderate Buy" and an average price target of $182.12.

Insider Transactions at Natera

In other news, insider John Fesko sold 343 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $145.55, for a total value of $49,923.65. Following the completion of the sale, the insider now directly owns 156,946 shares in the company, valued at approximately $22,843,490.30. The trade was a 0.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 87,272 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the completion of the sale, the chief executive officer now owns 203,354 shares of the company's stock, valued at $29,160,963.60. The trade was a 30.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 152,436 shares of company stock worth $22,019,079. 7.60% of the stock is owned by insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.